BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $275,464 | -19.2% | 7,299 | -2.4% | 0.01% | -18.8% |
Q2 2023 | $340,789 | +14.8% | 7,480 | +2.2% | 0.02% | +6.7% |
Q1 2023 | $296,899 | -21.0% | 7,320 | -0.7% | 0.02% | -21.1% |
Q4 2022 | $375,666 | -8.8% | 7,370 | -3.7% | 0.02% | -17.4% |
Q3 2022 | $412,000 | -5.5% | 7,657 | +12.8% | 0.02% | 0.0% |
Q2 2022 | $436,000 | -17.6% | 6,786 | -0.6% | 0.02% | -4.2% |
Q1 2022 | $529,000 | -10.2% | 6,826 | -0.6% | 0.02% | -4.0% |
Q4 2021 | $589,000 | -21.4% | 6,866 | -26.3% | 0.02% | -28.6% |
Q3 2021 | $749,000 | -3.6% | 9,311 | -3.5% | 0.04% | -2.8% |
Q2 2021 | $777,000 | -17.2% | 9,651 | -13.2% | 0.04% | -21.7% |
Q1 2021 | $938,000 | +8.9% | 11,121 | +3.6% | 0.05% | -2.1% |
Q4 2020 | $861,000 | -1.3% | 10,730 | -1.0% | 0.05% | -13.0% |
Q3 2020 | $872,000 | -19.5% | 10,842 | -13.8% | 0.05% | -22.9% |
Q2 2020 | $1,083,000 | +6.3% | 12,577 | +0.2% | 0.07% | -10.3% |
Q1 2020 | $1,019,000 | -19.9% | 12,547 | -17.5% | 0.08% | +11.4% |
Q4 2019 | $1,272,000 | -4.1% | 15,207 | +0.3% | 0.07% | -11.4% |
Q3 2019 | $1,326,000 | +12.4% | 15,162 | +5.3% | 0.08% | +9.7% |
Q2 2019 | $1,180,000 | +66.7% | 14,404 | +65.4% | 0.07% | +63.6% |
Q1 2019 | $708,000 | +35.6% | 8,706 | +9.9% | 0.04% | +18.9% |
Q4 2018 | $522,000 | -13.1% | 7,923 | +1.7% | 0.04% | +2.8% |
Q3 2018 | $601,000 | -3.2% | 7,793 | -7.3% | 0.04% | 0.0% |
Q2 2018 | $621,000 | +20.1% | 8,406 | +5.8% | 0.04% | +12.5% |
Q1 2018 | $517,000 | -4.3% | 7,947 | -4.8% | 0.03% | +3.2% |
Q4 2017 | $540,000 | +6.5% | 8,347 | +2.6% | 0.03% | -6.1% |
Q3 2017 | $507,000 | +3.9% | 8,137 | +0.2% | 0.03% | +3.1% |
Q2 2017 | $488,000 | +19.3% | 8,117 | +2.9% | 0.03% | +18.5% |
Q1 2017 | $409,000 | +7.6% | 7,887 | -8.0% | 0.03% | +3.8% |
Q4 2016 | $380,000 | -9.7% | 8,577 | -2.3% | 0.03% | -13.3% |
Q3 2016 | $421,000 | +2.4% | 8,781 | -3.3% | 0.03% | +3.4% |
Q2 2016 | $411,000 | +3.8% | 9,082 | -5.8% | 0.03% | 0.0% |
Q1 2016 | $396,000 | -3.9% | 9,642 | -10.7% | 0.03% | -6.5% |
Q4 2015 | $412,000 | +14.4% | 10,802 | -1.3% | 0.03% | +10.7% |
Q3 2015 | $360,000 | -55.3% | 10,948 | -4.9% | 0.03% | -49.1% |
Q2 2015 | $805,000 | +1.6% | 11,508 | -0.4% | 0.06% | +1.9% |
Q1 2015 | $792,000 | -6.9% | 11,555 | -0.5% | 0.05% | -19.4% |
Q4 2014 | $851,000 | -6.3% | 11,610 | -8.2% | 0.07% | -14.1% |
Q3 2014 | $908,000 | -6.8% | 12,647 | -6.1% | 0.08% | -7.1% |
Q2 2014 | $974,000 | -1.9% | 13,470 | -0.2% | 0.08% | -6.7% |
Q1 2014 | $993,000 | +3.3% | 13,495 | -2.3% | 0.09% | -4.3% |
Q4 2013 | $961,000 | -0.4% | 13,817 | -5.9% | 0.09% | -13.0% |
Q3 2013 | $965,000 | -7.9% | 14,686 | -2.9% | 0.11% | -17.6% |
Q2 2013 | $1,048,000 | – | 15,126 | – | 0.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |